[Federal Register Volume 75, Number 211 (Tuesday, November 2, 2010)]
[Notices]
[Page 67366]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-27604]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30-Day-11-0307]


Agency Forms Undergoing Paperwork Reduction Act Review

    The Centers for Disease Control and Prevention (CDC) publishes a 
list of information collection requests under review by the Office of 
Management and Budget (OMB) in compliance with the Paperwork Reduction 
Act (44 U.S.C. chapter 35). To request a copy of these requests, call 
404-639-4604 or send comments to Carol Walker, CDC Acting Reports 
Clearance Officer, 1600 Clifton Road, MS-D74, Atlanta, GA 30333 or send 
an e-mail to <a href="/cdn-cgi/l/email-protection#e38c8e81a3808780cd848c95"><span class="__cf_email__" data-cfemail="91fefcf3d1f2f5f2bff6fee7">[email protected]</span></a>. Send written comments to CDC Desk Officer, 
Office of Management and Budget, Washington, DC or by fax to (202) 395-
5806. Written comments should be received within 30 days of this 
notice.

Proposed Project

    Gonococcal Isolate Surveillance Project (GISP), (OMB No. 0920-
0307)--Extension--National Center for HIV/AIDS, Viral Hepatitis, STD, 
and TB Prevention (NCHHSTP), Centers for Disease Control and Prevention 
(CDC).

Background and Brief Description

    CDC is requesting a 3-year extension without change for this 
project. The objectives of GISP are to monitor trends in antimicrobial 
susceptibility of Neisseria gonorrhoeae strains in the U.S. and to 
characterize resistant isolates. Monitoring antibiotic susceptibility 
is critical since Neisseria gonorrhoeae has demonstrated the consistent 
ability to gain antibiotic resistance. GISP provides critical 
surveillance for antimicrobial resistance, allowing for informed 
treatment recommendations.
    This project involves 5 regional laboratories and 30 sexually 
transmitted disease (STD) clinics operated by the local health 
departments around the country. The STD clinics submit up to 25 
gonococcal isolates per month to the Regional laboratories to measure 
susceptibility to a panel of antibiotics. Limited demographic and 
clinical information corresponding to the isolates are submitted 
directly by the STD clinics to CDC.
    During 1986-2009, GISP has demonstrated the ability to effectively 
achieve its objectives. The emergence of resistance in the United 
States to penicillin, tetracyclines, and fluoroquinolones among N. 
gonorrhoeae isolates was identified through GISP. Increased prevalence 
of fluoroquinolone-resistant N. gonorrhoeae (QRNG), as documented by 
GISP data, prompted CDC to update the treatment recommendations for 
gonorrhea in CDC's Sexually Transmitted Diseases Treatment Guidelines, 
2006 and to release an MMWR article stating that CDC no longer 
recommended fluoroquinolones for treatment of gonococcal infections. 
There are no costs to respondents other than their time. Respondents 
receive Federal funds to participate in this project. The total annual 
burden is estimated to be 8,568 hours.

----------------------------------------------------------------------------------------------------------------
                                                                                  Number of      Average burden
         Type of respondent                Form name            Number of       responses per     per response
                                                               respondents       respondent        (in hours)
----------------------------------------------------------------------------------------------------------------
Clinic.............................  Form 1...............                30               240             11/60
Laboratory.........................  Form 2...............                 5             1,440                 1
                                     Form 3...............                 5                48             12/60
                                                           -----------------------------------------------------
    Total..........................  .....................                40  ................  ................
----------------------------------------------------------------------------------------------------------------


    Dated: October 27, 2010.
Carol Walker,
Acting Reports Clearance Officer, Centers for Disease Control and 
Prevention.
[FR Doc. 2010-27604 Filed 11-1-10; 8:45 am]
BILLING CODE 4163-18-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>